Semaglutide 1.5mg: what is the starting dose for Wegovy tablets?

Why does semaglutide 1.5mg exist as a starting dose rather than a treatment dose?

A common misconception is that a lower dose simply means weaker treatment, something to power through as quickly as possible. That's not quite right. The 1.5mg starting dose is there because GLP-1 medicines slow gastric emptying and act on appetite centres in the brain, changes that the body notices. Beginning at a low dose gives your digestive system time to adjust before the levels that produce meaningful weight loss are reached.

Nausea, loose stools and indigestion are the most common early side effects of oral semaglutide, precisely the kind of effects that a gradual ramp makes more manageable. The prescriber's job is to move you through the schedule at a pace your system tolerates, which is why the minimum at each level is one month and why timing is their decision, not a self-managed one.

The semaglutide overview on this site explains more about how the medicine works at a biological level, including how it differs from the injectable form. Worth reading if you want the mechanism before you reach a prescriber.

How does semaglutide 1.5mg fit into the full Wegovy tablet schedule?

Once-daily oral semaglutide for weight management follows four steps: 1.5mg, then 4mg, then 9mg, and finally the 25mg maintenance dose, and if you want to understand what that top end of the schedule involves, the semaglutide 5 page covers the higher-dose territory in detail. At least four weeks must pass at each level before moving up, a schedule that typically means several months before maintenance is reached. Patients who are already established on the 2.4mg weekly Wegovy injection may be able to start directly at 25mg tablets, but that transition is a clinical assessment, not a patient-led swap.

How you take the tablet matters as much as the dose itself. It needs to go down first thing in the morning, on a completely empty stomach, with no more than about 120ml of plain water. Then nothing (no food, no coffee, no other medicines) for at least 30 minutes. Missing that window or taking it with a meal reduces how much semaglutide actually gets absorbed. Unlike the injection, there's no refrigeration required, which makes the tablet genuinely convenient for travel.

If you're weighing injection versus tablet options, the 1mg semaglutide dose page covers one of the injectable steps, and the 2mg dose page walks through the next. The formats work differently and suit different people.

What do the trial results show for oral semaglutide at this dose ladder?

Phase 3 evidence for the Wegovy tablet comes from the OASIS 4 trial, 307 adults with obesity or overweight and at least one weight-related condition, without diabetes, over 64 weeks alongside lifestyle changes. Average weight loss across all participants reached around 13.6%, compared with roughly 2.4% on placebo. Among those who adhered fully to treatment throughout the trial, the figure was closer to 17%, though that second number only applies to that specific, fully-adherent group, not as a general expectation.

The most commonly reported side effects in OASIS 4 were gastrointestinal: nausea, diarrhoea, vomiting and constipation, reported by around 74% of participants on oral semaglutide compared with 42% on placebo. Most were mild to moderate and settled over time, consistent with what clinicians see with injectable semaglutide and tirzepatide. The NHS semaglutide medicines page covers side effects in full and is worth bookmarking once you start treatment.

For context on what the 3mg tablet represents, it's worth being clear: that strength is Rybelsus, a diabetes medicine with a completely separate licence. It is not a rung on the Wegovy weight-loss ladder. A prescriber will clarify this if it comes up, but the distinction matters for anyone researching semaglutide doses online.

Who might be considered for the Wegovy tablet, and what does starting treatment actually involve?

The MHRA-approved licence for oral semaglutide covers adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition such as high blood pressure, raised cholesterol or prediabetes, used alongside a reduced-calorie diet and increased physical activity. A BMI figure alone doesn't determine suitability; the full clinical picture matters, including other medicines, existing conditions and the prescriber's assessment of risk versus benefit.

Wegovy tablets are not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. The medicine is not licensed for under-18s. Anyone taking oral contraceptives should discuss timing with their prescriber, since there is evidence that absorption of the pill can be affected during the first weeks of a new GLP-1 or after each dose increase.

The Wegovy tablet is currently available through private prescription only, NICE has not yet appraised it, and no NHS commissioning pathway exists. For a broader look at what private weight-loss treatment costs and what to reasonably expect, the weight-loss treatment overview is a practical starting point. If you'd like to know whether the Wegovy tablet might be appropriate for you specifically, a consultation with our prescribers is the right next step, they review every case the same day it comes in, and there's no charge for the consultation itself.